Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

Discover the emerging science in atopic dermatitis (AD) from experts in the field.

DUPIXENT Webinars 2020

Q&A WEBINAR EXCERPT

An excerpt from the “Managing moderate-to-severe AD” Q&A following the Sanofi-sponsored BAD 2020 symposium.

ADvance 2019

DUPIXENT in adolescents with moderate-to-severe AD

DR BEN WALKER

Discusses the policies that govern access to dupilumab for adolescents with moderate-to-severe atopic dermatitis in the UK.

SEVERAL EXPERTS

Discuss how do you define a ‘moderate’ patient – adult or adolescent?

DR TESS MCPHERSON

Discusses the opportunities and challenges of managing adolescent patients with atopic dermatitis.

TEENA MACKENZIE

Discusses the role of a Dermatology nurse in managing and supporting adolescents with moderate-to-severe atopic dermatitis and their carers.

DR TIM CLAYTON

Discusses the pathophysiology of atopic dermatitis and the treatment options for adolescents with moderate-to-severe disease.

PROFESSOR MICHAEL CORK

Discusses the role of DUPIXENT in the treatment of adolescents with moderate-to-severe atopic dermatitis.

ADvance 2018

DUPIXENT in adults with moderate-to-severe AD

DR ANTHONY BEWLEY

Discusses atopic dermatitis and the mind.

PROFESSOR MICHAEL CORK

Discusses the unmet need in atopic dermatitis.

PROFESSOR ALAN IRVINE

Discusses the pathophysiology of atopic dermatitis and key DUPXIENT trial data.

AD, atopic dermatitis; BAD, British Association of Dermatologists

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: March 2021.